Congenital nephrotic syndrome responsive to captopril and indometacin.
Two children with congenital nephrotic syndrome are described (one with Finnish-type nephrosis, the other with diffuse mesangial sclerosis). Both children have had a prolonged and sustained clinical response with good physical health and normal growth patterns using captopril and indometacin as their sole treatment. No adverse effects have been noted. We recommend a trial of indometacin and captopril treatment in cases of congenital nephrotic syndrome.
Heaton
P A
PA
Taranaki Base Hospital, Private Bag 2016, New Plymouth 4620, New Zealand. paed.cacc@thcl.co.nz
Smales
O
O
Wong
W
W
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007223:Infant; D009404:Nephrotic Syndrome / Q000151:congenital* / Q000188:drug therapy; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002216:Captopril; D007213:Indomethacin